{"id":"https://openalex.org/W790850232","doi":null,"title":"Combination of non-cytotoxic agents with anti-angiogenic activity for metronomic therapy of solid tumors: A Phase II study","display_name":"Combination of non-cytotoxic agents with anti-angiogenic activity for metronomic therapy of solid tumors: A Phase II study","publication_year":2004,"publication_date":"2004-04-01","ids":{"openalex":"https://openalex.org/W790850232","mag":"790850232"},"language":"en","primary_location":{"id":"mag:790850232","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/64/7_Supplement/1058.4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003897511","display_name":"Giuseppe Curigliano","orcid":"https://orcid.org/0000-0003-1781-2518","observed_orcids":["https://orcid.org/0000-0003-1781-2518"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Curigliano","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":"https://orcid.org/0000-0003-1781-2518","affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034667041","display_name":"Cristina Noberasco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Cristina Noberasco","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069836898","display_name":"Francesco Bertolini","orcid":"https://orcid.org/0000-0001-5660-3255","observed_orcids":["https://orcid.org/0000-0001-5660-3255"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesco Bertolini","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":"https://orcid.org/0000-0001-5660-3255","affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067487266","display_name":"Alessandra Milani","orcid":"https://orcid.org/0000-0003-0403-3128","observed_orcids":["https://orcid.org/0000-0003-0403-3128"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandra Milani","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":"https://orcid.org/0000-0003-0403-3128","affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033058370","display_name":"Sara Manzoni","orcid":"https://orcid.org/0000-0002-8902-1240","observed_orcids":["https://orcid.org/0000-0002-8902-1240","https://orcid.org/0009-0009-1119-5986"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Sara Manzoni","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":"https://orcid.org/0000-0002-8902-1240","affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046510679","display_name":"Lucia Dodaro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Lucia Dodaro","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040885322","display_name":"Andrea Rocca","orcid":"https://orcid.org/0000-0003-4613-8884","observed_orcids":["https://orcid.org/0000-0003-4613-8884"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Andrea Rocca","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":"https://orcid.org/0000-0003-4613-8884","affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009935310","display_name":"Filippo de Braud","orcid":"https://orcid.org/0000-0003-0103-730X","observed_orcids":["https://orcid.org/0000-0003-0103-730X"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Filippo de Braud","raw_affiliation_strings":["(European Institute of Oncology, Milan, Italy)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"(European Institute of Oncology, Milan, Italy)","institution_ids":["https://openalex.org/I6141010"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I6141010"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"64","issue":null,"first_page":"1058","last_page":"1059"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metronomic-chemotherapy","display_name":"metronomic chemotherapy","score":0.9559999704360962},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.9269999861717224},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.9369999766349792},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":1.0},{"id":"https://openalex.org/keywords/celecoxib","display_name":"celecoxib","score":1.0},{"id":"https://openalex.org/keywords/metastatic-solid-tumors","display_name":"metastatic solid tumors","score":0.8600000143051147},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8579999804496765},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":1.0},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.6710000038146973},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5090000033378601},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5389999747276306},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.5389999747276306},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.5189999938011169},{"id":"https://openalex.org/keywords/leukopenia","display_name":"leukopenia","score":0.6100000143051147},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.3880000114440918},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.4970000088214874},{"id":"https://openalex.org/keywords/metastatic-thyroid-carcinoma","display_name":"metastatic thyroid cancer","score":0.33000001311302185}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9119346737861633},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.9026515483856201},{"id":"https://openalex.org/C2776467144","wikidata":"https://www.wikidata.org/wiki/Q408801","display_name":"Celecoxib","level":2,"score":0.7435735464096069},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5034932494163513},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5034500956535339},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4453851282596588},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43995341658592224},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.42065003514289856},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41428685188293457},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33873796463012695},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.27307790517807007}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:790850232","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/64/7_Supplement/1058.4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2033723622","https://openalex.org/W2277276585","https://openalex.org/W2004919077","https://openalex.org/W2218471737","https://openalex.org/W4251774223","https://openalex.org/W2001727698","https://openalex.org/W2591157125","https://openalex.org/W2082626444","https://openalex.org/W2127680641","https://openalex.org/W1978855912"],"abstract_inverted_index":{"Proc":[0],"Amer":[1],"Assoc":[2],"Cancer":[3],"Res,":[4],"Volume":[5],"45,":[6],"2004\n\n4583":[7],"\n\nSuccessful":[8],"cancer":[9],"therapies":[10],"targeting":[11],"the":[12,20,84,191,316,363],"tumor":[13,27],"vasculature":[14],"would":[15],"be":[16,403,413],"expected":[17],"to":[18,25,74,89,96,194,281,315],"block":[19],"existing":[21],"blood":[22],"supply":[23],"and":[24,32,44,179,188,212,296,309,325,335,352,407],"prevent":[26],"neovascularization.":[28],"To":[29],"evaluate":[30],"safety":[31],"toxicity":[33,276,302],"of":[34,39,66,77,146,169,238,257,393,418],"metronomic":[35],"long":[36,342,390],"term":[37,391],"administration":[38,145,392],"alpha":[40],"interferon":[41],"(IFN\u03b1),":[42],"thalidomide":[43,102,108,124,130,136,152,381,398],"celecoxib":[45,110,116,122,128,134,156,379,396],"we":[46,92,246],"designed":[47],"a":[48,63,347,367,405],"randomized,":[49],"open":[50],"label":[51],"phase":[52],"II":[53,311],"clinical":[54,260],"trial.":[55],"Patients":[56,172,340],"with":[57,62,182,319,341,378],"proven":[58],"metastatic":[59],"solid":[60],"tumors":[61,216],"slow":[64],"rate":[65],"growth,":[67],"defined":[68],"as":[69,304,415],"free":[70],"interval":[71],"from":[72,373],"treatment":[73],"progression":[75],">":[76],"6":[78,97,270],"months,":[79],"were":[80,328],"considered":[81,404,414],"suitable":[82],"for":[83,161,185,198,244],"study.":[85],"From":[86],"January":[87],"2002":[88],"November":[90],"2003":[91],"randomized":[93],"34":[94],"patients":[95,203,242,258,317],"groups:":[98],"A1.":[99],"IFN\u03b1":[100,106,114,120,138,394],"+":[101,107,109,115,121,123,129,135,137,264,395,397],"(5":[103,125],"patients),":[104,118],"A2.":[105],"(6":[111,117,131,139],"patients).":[112,126,132,140],"B1.":[113],"B2.":[119],"C1.":[127],"C2.":[133],"Treatment":[141],"plan":[142],"included":[143,173,289],"daily":[144],"subcutaneous":[147],"alpha-interferon":[148],"0.5":[149],"MU/12":[150],"hrs,":[151],"100":[153],"mg/daily":[154],"orally,":[155],"200":[157],"mg/12":[158],"hrs":[159],"orally":[160],"at":[162],"least":[163],"4":[164,218,236],"months":[165,187,237,271,338],"even":[166],"in":[167,174,307,312,350,357,362,370],"presence":[168],"progressive":[170],"disease.":[171],"drugs":[175,184],"arm":[176],"A2,":[177],"B2":[178],"C2":[180],"started":[181],"2":[183,186,228,232],"than":[189,269],"added":[190],"third":[192],"drug":[193],"combination,":[195],"continuing":[196],"therapy":[197,334],"two":[199,337],"additional":[200],"months.":[201],"Thirteen":[202],"had":[204,209,214,259,346],"renal":[205,374],"cell":[206],"carcinoma,":[207,211,224,376],"9":[208],"hepatocellular":[210],"12":[213],"other":[215],"(":[217],"medullary":[219],"thyroid":[220,223],"carcinoma,1":[221],"follicular":[222],"3":[225],"prostatic":[226],"cancer,":[227],"unknown":[229],"primary":[230],"tumor,":[231],"neuroendocrine":[233],"tumors).":[234],"After":[235],"treatment,":[239],"among":[240],"30":[241],"evaluable":[243],"response,":[245],"observed":[247,279,300,361],"1":[248],"partial":[249,368],"response":[250,263,369],"(3%)":[251],"20":[252],"stable":[253,265,344],"disease":[254,266,345],"(67%).":[255],"47%":[256],"benefit":[261],"(partial":[262],"lasting":[267,343],"more":[268],").":[272],"No":[273],"grade":[274,305,310],"IV":[275],"has":[277],"been":[278],"according":[280],"NCI":[282],"criteria.":[283],"Grade":[284],"III":[285],"common":[286],"adverse":[287],"events":[288],"leucopenia":[290],"(7%);":[291],"anemia":[292],"(3%);":[293],"asthenia":[294],"(7%),":[295],"lethargy":[297],"(7%).":[298],"We":[299],"skin":[301],"scored":[303],"I":[306],"17%":[308],"20%":[313],"limited":[314],"treated":[318,377],"celecoxib.":[320],"Circulating":[321],"endothelial":[322],"cells":[323,375],"(CEC)":[324],"progenitors":[326],"(CEP)":[327],"measured":[329],"by":[330,425],"flow":[331],"cytometry":[332],"before":[333],"every":[336],"thereafter.":[339],"significant":[348],"decrease":[349],"CEC":[351,359,411],"CEP":[353],"counts.":[354],"An":[355],"increase":[356],"apoptotic":[358],"was":[360],"patient":[364],"who":[365],"achieved":[366],"lung":[371],"metastasis":[372],"plus":[380],"(arm":[382],"C1).":[383],"These":[384],"promising":[385],"data":[386],"suggest":[387],"that":[388],"metronomic,":[389],"different":[399],"combination":[400],"schedules":[401],"can":[402],"safe":[406],"active":[408],"antitumor":[409],"treatment.":[410],"could":[412],"surrogate":[416],"marker":[417],"antiangiogenic":[419],"activity.":[420],"This":[421],"study":[422],"is":[423],"supported":[424],"AIRC":[426]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}